All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
OncLive® On Air
32 minutes
1 month ago
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.
OncLive® On Air
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
